1Zhou C,Wu Y L,Chen G. Efficacy results from the randomised phase Ⅲ OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM),in Chinese advanced non-smallcell lung cancer (NSCLC) patients (pts) with EGFR activating mutations[J].Annals of Oncology,2010,(z8):viii1-viii12.LBA13.
2Wu Y L,Zhou C,Chen G. First biomarker analyses from a phase Ⅲ,randomised,open-label,first-line study of erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese patients (pts) with advanced non-small-cell lung cancer (NSCLC) with EGFR activating mutations (OPTIMAL,CTONG 0802)[J].Annals of Oncology,2010,(z8):viii1-viii12.LBA14.
3Rosell R,Gervais R,Vergnenegre A. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations:Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase Ⅲ randomized trial[J].Journal of Clinical Oncology,2011,(Suppl):Abstr7503.
4Zhang L,Shenglin M,Song X. Efficacy,tolerability,and biomarker analyses from a phase Ⅲ,randomized,placebo-controlled,parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC;INFORM;CTONG0804)[J].Journal of Clinical Oncology,2011,(Suppl):AbstrLBA7511.
5Paz-Ares L G,de Marinis F,Dediu M. PARAMOUNT:Phase Ⅲ study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)[J].Journal of Clinical Oncology,2011,(Suppl):AbstrCRA7510.
6Barlesi F,de Castro J,Dvornichenko V. AVAPERL (MO22089):Final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) rancomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+ pemetrexed (pem) after first-line (1L) bev-cisplatin (cis)-pem treatment (tx)[J].European Journal of Cancer,2011,(z2):AbstrLBA34.
7Sun Y,Shi Y,Zhang L. A randomized,doubleblind phase Ⅲ study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN)[J].Journal of Clinical Oncology,2011,(Suppl):Abstr7522.
8Shaw A T,Yeap B Y,Solomon B J. Impact of crizotinib on survival in patients with advanced,ALK-positive NSCLC compared with historical controls[J].Journal of Clinical Oncology,2011,(Suppl):Abstr7507.
9Kim L,Crin D,Riely G J. Initial phase Ⅱ results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC):PROFILE 1005[J].Journal of Clinical Oncology,2011,(Suppl):Abstr7514.
10Spigel D R,Ervin T J,Ramlau R. Randomized,phase Ⅱ multicenter,double-blind,placebo-controlled study evaluating MetMAb,an antibody to Met receptor,in combination with erlotinib,in patients with advanced non-small-cell lung cancer (OAM4558g)[J].Annals of Oncology,2010,(z8):viiil-viiil2.LBA15.
二级参考文献25
1GAZDAR AF, MINNA JD. Molecular detection of early lung cancer [J]. J Nati Cancer Inst, 1999, 91(4):299-301.
2MELAMED MR, FLEHINGER BJ, ZAMAN MB, et al. Screening for lung cancer: results of the Memorial Sloan-Kettering study in New York [J]. Chest, 1984, 86(1):44-53.
3FONTANA RS, SANDERSON DR, WOOLNER LB, et al. Lung cancer screening: the Mayo program [J]. J Occup Med, 1986, 28(8) :746-750.
5PASTORINO U, BELLOMI M, LANDONI C, et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results [J]. Lancet, 2003, 362(9384) :593-597.
6NAWA T, NAKAGAWA T, KUSANO S, et al. Lung cancer screening using low-dose spiral CT: results of baseline and 1- year follow-up studies[J]. Chest, 2002, 122(1):15-20.
7SONE S, TAKASHIMA S, LI F, et al. Mass screening for lung cancer with mobile spiral computed tomography scanner [J]. Lancet,1998, 351(9111) :1242-1245.
8HENSCHKE CI. Early lung cancer action project: overall design and findings from baseline screening [J]? Cancer Suppl, 2000, 89(11) :2474-2482.
9HENSCHKE CI, NAIDICH DP, YANKELEVITZ DF, et al. Early lung cancer action project: initial findings on repeat screening [J]. Cancer, 2001, 92(1) : 153-159.
10DIEDERICH S, WORMANNS D, SEMIK M, et al. Screening for early lung cancer with low-dose spiral CT: prevalence in 817 asymptomatic smokers [J]. Radiology, 2002, 222 (3) : 773-781.
6Leighl NB. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third--line[J]. Curt Oncol, 2012, 19(Suppl 1):$52-$58.
7Zhang L, Yang H, Zhao Y, et al. Detection of EGFR Somatic Muta- tions in Non-SmaU Cell Lung Cancer (NSCLC) Using a Novel Mutant-Enriched Liquidchip (MEL) Technology[J]. Curt Drug Metab, 2012, 13(7):1007-1011.
8Scagliotti GV, Parikh P, von PawelJ, et al. Phase 1II study compar- ing cisplatin plus gemcitabine with cisplatin plus pemetrexed in che- motherapy-na'l've patients with advanced-stage non--small--cell lung cancer[J].J Clin Oncol, 2008, 26(21):3543--3551.
9Lee HY, Ahn HK, JeongJY, et al. Favorable clinical outcomes of pemetrexed treatment in anaplasfic lymphoma kinase positive non-small-cell lung cancer[J]. Lung Cancer, 2013,79(1):40-45.
10SunJM, HanJ, AhnJS, et al. Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non--small cell lung cancer treated with pemetrexed-based chemo- therapy[J].J Thorac Oncol, 2011, 6(8):1392-1399.
